MX2024006649A - Composiciones y metodos para el tratamiento del dolor. - Google Patents
Composiciones y metodos para el tratamiento del dolor.Info
- Publication number
- MX2024006649A MX2024006649A MX2024006649A MX2024006649A MX2024006649A MX 2024006649 A MX2024006649 A MX 2024006649A MX 2024006649 A MX2024006649 A MX 2024006649A MX 2024006649 A MX2024006649 A MX 2024006649A MX 2024006649 A MX2024006649 A MX 2024006649A
- Authority
- MX
- Mexico
- Prior art keywords
- branched
- sirna
- molecules
- pain
- sirna molecules
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 101150080511 Scn9a gene Proteins 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284957P | 2021-12-01 | 2021-12-01 | |
| PCT/US2022/080764 WO2023102488A2 (en) | 2021-12-01 | 2022-12-01 | Compositions and methods for treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006649A true MX2024006649A (es) | 2024-08-15 |
Family
ID=86613161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006649A MX2024006649A (es) | 2021-12-01 | 2022-12-01 | Composiciones y metodos para el tratamiento del dolor. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250109402A1 (https=) |
| EP (1) | EP4441228A2 (https=) |
| JP (1) | JP2024542738A (https=) |
| KR (1) | KR20240131349A (https=) |
| CN (1) | CN118632929A (https=) |
| AU (1) | AU2022403005A1 (https=) |
| CA (1) | CA3240948A1 (https=) |
| MX (1) | MX2024006649A (https=) |
| WO (1) | WO2023102488A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025108284A1 (en) * | 2023-11-20 | 2025-05-30 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of sodium voltage-gated channel alpha subunit 9 (scn9a) |
| WO2025140551A1 (en) * | 2023-12-29 | 2025-07-03 | Neuro3 Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009033027A2 (en) * | 2007-09-05 | 2009-03-12 | Medtronic, Inc. | Suppression of scn9a gene expression and/or function for the treatment of pain |
-
2022
- 2022-12-01 KR KR1020247021912A patent/KR20240131349A/ko active Pending
- 2022-12-01 CA CA3240948A patent/CA3240948A1/en active Pending
- 2022-12-01 EP EP22902400.5A patent/EP4441228A2/en active Pending
- 2022-12-01 AU AU2022403005A patent/AU2022403005A1/en active Pending
- 2022-12-01 CN CN202280087774.5A patent/CN118632929A/zh active Pending
- 2022-12-01 US US18/714,751 patent/US20250109402A1/en active Pending
- 2022-12-01 JP JP2024532733A patent/JP2024542738A/ja active Pending
- 2022-12-01 MX MX2024006649A patent/MX2024006649A/es unknown
- 2022-12-01 WO PCT/US2022/080764 patent/WO2023102488A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023102488A8 (en) | 2023-08-10 |
| EP4441228A2 (en) | 2024-10-09 |
| JP2024542738A (ja) | 2024-11-15 |
| KR20240131349A (ko) | 2024-08-30 |
| US20250109402A1 (en) | 2025-04-03 |
| WO2023102488A3 (en) | 2023-09-14 |
| CN118632929A (zh) | 2024-09-10 |
| WO2023102488A2 (en) | 2023-06-08 |
| AU2022403005A1 (en) | 2024-07-11 |
| CA3240948A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260069625A1 (en) | Organic compositions to treat kras-related diseases | |
| MX2021012126A (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central. | |
| MX2025003674A (es) | Composiciones de arnip y metodos dirigidos a acidos nucleicos de la proteina tau asociada a microtubulos | |
| MX2024006649A (es) | Composiciones y metodos para el tratamiento del dolor. | |
| WO2023283403A3 (en) | Bis-rnai compounds for cns delivery | |
| WO2022256565A3 (en) | Compositions and methods for delivering therapeutic oligonucleotides to the central nervous system | |
| JPWO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| Drzewińska et al. | Poly (propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity | |
| MX2025003632A (es) | Composiciones de arnip y metodos dirigidos a acidos nucleicos de alfa-sinucleina | |
| WO2024073589A8 (en) | Compositions and methods for treatment of neuroinflammatory diseases | |
| WO2024073604A3 (en) | Compositions and methods for treatment of neurodegenerative diseases | |
| WO2024073592A3 (en) | Compositions and methods for treatment of neurological disorders | |
| WO2021262919A3 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| MX2025003636A (es) | Composiciones y metodos para el tratamiento de la enfermedad de huntington | |
| WO2023102490A8 (en) | Compositions and methods for treatment of epilepsies | |
| WO2024073596A3 (en) | Compositions and methods for treatment of spinocerebellar ataxias | |
| WO2023225495A3 (en) | Compositions and methods for treatment of microsatellite dna expansion disorders | |
| WO2024073603A8 (en) | Compositions and methods for treatment of neuroinflammatory diseases | |
| US12473548B2 (en) | Modification of small RNAs for therapeutic uses | |
| WO2023031778A1 (en) | Chimeric complex and therapeutic uses thereof |